Drugs that combat aging may be available within five years, following landmark work led by an Australian researcher.
The work, published in Science, finally proves that a single anti-aging enzyme in the body can be targeted, with the potential to prevent age-related diseases and extend lifespans.
The paper shows all of the 117 drugs tested work on the single enzyme through a common mechanism. This means that a whole new class of anti-aging drugs is now viable, which could ultimately prevent cancer, Alzheimer’s disease and type 2 diabetes.
“Ultimately, these drugs would treat one disease, but unlike drugs of today, they would prevent 20 others,” says the lead author of the paper, Professor David Sinclair, from UNSW Medicine, who is based at Harvard University. “In effect, they would slow aging.”
The target enzyme, SIRT1, is switched on naturally by calorie restriction and exercise, but it can also be enhanced through activators. The most common naturally-occurring activator is resveratrol, which is found in small quantities in red wine, but synthetic activators with much stronger activity are already being developed.
Although research surrounding resveratrol has been going for a decade, until now the basic science had been contested. Despite this, there have already been promising results in some trials with implications for cancer, cardiovascular disease and cardiac failure, type 2 diabetes, Alzheimer’s and Parkinson’s diseases, fatty liver disease, cataracts, osteoporosis, muscle wasting, sleep disorders and inflammatory diseases such as psoriasis, arthritis and colitis (inflammatory bowel disease).
“In the history of pharmaceuticals, there has never been a drug that tweaks an enzyme to make it run faster,” says Professor Sinclair, a geneticist with the Department of Pharmacology at UNSW.
The technology was sold to pharmaceutical giant GlaxoSmithKline in 2008[i]. Four thousand synthetic activators, which are 100 times as potent as a single glass of red wine, have been developed — the best three are in human trials.
“Our drugs can mimic the benefits of diet and exercise, but there is no impact on weight,” says Professor Sinclair, who suggests the first therapeutic to be marketed will be for diabetes.
There have been limited trials in people with type 2 diabetes and the skin inflammatory disease, psoriasis. There were benefits to the metabolism in the first group and a reduction in skin redness in the second.
The drugs can be administered orally, or topically. So far, there have been no drugs developed targeting aging skin, but one major skin care range has developed a crème with resveratrol in it.
While any drug would be strictly prescribed for certain conditions, Professor Sinclair suggests that one day, they could be taken orally as a preventative. This would be in much the same way as statin drugs are commonly prescribed to prevent, instead of simply treating, cardiovascular disease.
In animal models, overweight mice given synthetic resveratrol were able to run twice as far as slim mice and they lived 15 per cent longer.
“Now we are looking at whether there are benefits for those who are already healthy. Things there are also looking promising,” says Professor Sinclair, who also heads the Lowy Cancer Research Centre’s Laboratory for aging Research at UNSW.
“We’re finding that aging isn’t the irreversible affliction that we thought it was,” he says. “Some of us could live to 150, but we won’t get there without more research.”
[i] Professor Sinclair formed a started up company Sirtris to develop the anti-aging technology. This was subsequently sold to GlaxoSmithKline (GSK). Professor Sinclair is now a scientific advisor to GSK. Several other authors on the paper work for GSK or an affiliated company.
Health-e-Solutions comment: Sounds promising! So did statin drugs when they first came out. After years of use, their dangers are finally coming to the forefront. It will be interesting to watch the research unfold on this, but it cannot hurt to start eating healtier and exercising more to creat the same, although less potent effect. It may turn out that this is the best approach after all. We definitely think it is currently.
Until #CuringType1Diabetes is a reality within our reach, put your body in a position of strength to #MasterDiabetes the healthiest way possible. Lifestyle innovations as a priority over drug therapies may be the solution. Poor health feeds poor health in a vicious cycle, or negative feedback loop that is increasingly difficult to break the longer it continues. Promoting, supporting and creating health set in motion a positive feedback loop instead. Get tools and solutions to help minimize consequences and maximize benefits for nutrition, environment, exercise, sleep and stress management. These five health components make up the five pillars of health and nutrition in the Health-e-Solutions lifestyle. We’ll teach you how to improve each of these areas to help you #MasterDiabetes in the healthiest way possible.
Journal Reference: B. P. Hubbard, A. P. Gomes, H. Dai, J. Li, A. W. Case, T. Considine, T. V. Riera, J. E. Lee, S. Y. E, D. W. Lamming, B. L. Pentelute, E. R. Schuman, L. A. Stevens, A. J. Y. Ling, S. M. Armour, S. Michan, H. Zhao, Y. Jiang, S. M. Sweitzer, C. A. Blum, J. S. Disch, P. Y. Ng, K. T. Howitz, A. P. Rolo, Y. Hamuro, J. Moss, R. B. Perni, J. L. Ellis, G. P. Vlasuk, D. A. Sinclair. Evidence for a Common Mechanism of SIRT1 Regulation by Allosteric Activators. Science, 2013; 339 (6124): 1216 DOI:10.1126/science.1231097